clonidine has been researched along with paroxetine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Brunello, N; Galimberti, R; Racagni, G; Riva, M; Rovescalli, AC | 1 |
| Arora, RC; Crayton, J; Gulati, A | 1 |
| Baker, GB; Bourin, M; Colombel, MC; Redrobe, JP | 1 |
| Berger, M; Billiard, M; Chalabreysse, M; Durst, P; Palazzolo, J; Peyrelong, JP; Vialle, A | 1 |
| Bourin, M; Hascoët, M; Massé, F | 1 |
| Elliott, PM; Frenneaux, MP; McKenna, WJ; Mist, B; Murphy, RT; Shah, JS; Thaman, R; Williams, L | 1 |
| Baber, R; Hickey, M; Kwik, M | 1 |
| Alexander, IM; Moore, A | 1 |
| Isoherranen, N; Ke, AB; Nallani, SC; Rostami-Hodjegan, A; Unadkat, JD; Zhao, P | 1 |
3 review(s) available for clonidine and paroxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Clonidine; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Health Behavior; Hot Flashes; Humans; Menopause; Norpregnenes; Paroxetine; Personal Health Services; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Tamoxifen | 2005 |
Treating vasomotor symptoms of menopause: the nurse practitioner's perspective.
Topics: Adrenergic alpha-Agonists; Algorithms; Amines; Citalopram; Clonidine; Complementary Therapies; Cyclohexanecarboxylic Acids; Estrogen Replacement Therapy; Evidence-Based Medicine; Female; Fluoxetine; Gabapentin; gamma-Aminobutyric Acid; Hot Flashes; Humans; Life Style; Menopause; Middle Aged; Nurse Practitioners; Paroxetine; Patient Education as Topic; Patient Selection; Practice Guidelines as Topic; Primary Health Care; Safety Management; Selective Serotonin Reuptake Inhibitors | 2007 |
1 trial(s) available for clonidine and paroxetine
| Article | Year |
|---|---|
Reversal of inappropriate peripheral vascular responses in hypertrophic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Cardiomyopathy, Hypertrophic, Familial; Clonidine; Cross-Over Studies; Double-Blind Method; Exercise Test; Female; Humans; Lower Extremity; Male; Paroxetine; Propranolol; Syncope, Vasovagal; Vasodilation | 2005 |
16 other study(ies) available for clonidine and paroxetine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Age-related changes in rat serotonergic and adrenergic systems and in receptor responsiveness to subchronic desipramine treatment.
Topics: Aging; Animals; Brain; Clonidine; Desipramine; Dihydroalprenolol; Hydroxyindoleacetic Acid; Imipramine; Ketanserin; Kinetics; Male; Paroxetine; Piperidines; Prazosin; Proteins; Rats; Rats, Inbred Strains; Receptors, Adrenergic; Receptors, Serotonin; Serotonin; Time Factors | 1988 |
Central serotonergic uptake mechanisms in hypertensive rats: effects of clonidine and centhaquin.
Topics: Animals; Binding, Competitive; Blood Pressure; Brain Chemistry; Brain Stem; Cell Membrane; Cerebral Cortex; Clonidine; Heart Rate; Hypertension; Imipramine; Neurons; Paroxetine; Piperazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Serotonin; Serotonin | 1993 |
Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amines; Animals; Antidepressive Agents; Apomorphine; Brain; Clonidine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Hypothermia; Indoles; Male; Mice; Motor Activity; Norepinephrine; Paroxetine; Pindolol; Piperazines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Swimming | 1998 |
[Methadone and sleep apnea syndrome].
Topics: Adult; Brain; Clonidine; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Hydroxyzine; Methadone; Methotrimeprazine; Opioid-Related Disorders; Paroxetine; Polysomnography; Sleep Apnea, Central; Sleep Stages; Substance Withdrawal Syndrome; Trimeprazine | 2005 |
alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Citalopram; Clonidine; Cyclohexanols; Cyclopropanes; Dose-Response Relationship, Drug; Drug Antagonism; Guanabenz; Male; Mice; Milnacipran; Motor Activity; Paroxetine; Punishment; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Venlafaxine Hydrochloride | 2005 |
A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.
Topics: Clonidine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Dextromethorphan; Female; Humans; Models, Biological; Paroxetine; Pregnancy; Theophylline | 2013 |